SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1552 5260 "

Sökning: L773:1552 5260

  • Resultat 21-30 av 479
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  •  
22.
  • Benedict, Christian, et al. (författare)
  • Self-reported sleep disturbance is associated with Alzheimer's disease risk in men
  • 2015
  • Ingår i: Alzheimer's & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 11:9, s. 1090-1097
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To study the association between self-reported sleep disturbances and dementia risk.METHODS: Self-reported sleep disturbances and established risk factors for dementia were measured in men at ages 50 (n = 1574) and 70 (n = 1029) years. Dementia incidence was determined by reviewing their patient history between ages 50 and 90 years. In addition, plasma levels of β-amyloid (Aβ) peptides 1-40 and 1-42 were measured at ages 70, 77, and 82 years.RESULTS: Cox regression demonstrated that men with self-reported sleep disturbances had a higher risk of developing dementia (+33%) and Alzheimer's disease (AD, +51%) than men without self-reported sleep disturbances (both P < .05). Binary logistic regression showed the increased risk for both dementia (+114%) and AD (+192%) were highest when sleep disturbance was reported at age 70 years (both P < .001). No group differences were found in Aβ levels.CONCLUSION: Improving sleep quality may help reduce the neurodegenerative risk in older men.
  •  
23.
  •  
24.
  • Bereczki, E., et al. (författare)
  • Synaptic proteins predict cognitive decline in Alzheimer's disease andLewy body dementia
  • 2016
  • Ingår i: Alzheimer's & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 12:11, s. 1149-1158
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction Our objective was to compare the levels of three synaptic proteins involved in different steps of the synaptic transmission: Rab3A, SNAP25, and neurogranin, in three common forms of dementia: Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia. Methods A total of 129 postmortem human brain samples were analyzed in brain regional specific manner exploring their associations with morphologic changes and cognitive decline. Results We have observed robust changes reflecting synaptic dysfunction in all studied dementia groups. There were significant associations between the rate of cognitive decline and decreased levels of Rab3 in DLB in the inferior parietal lobe and SNAP25 in AD in the prefrontal cortex. Of particular note, synaptic proteins significantly discriminated between dementia cases and controls with over 90% sensitivity and specificity. Discussion Our findings suggest that the proposition that synaptic markers can predict cognitive decline in AD, should be extended to Lewy body diseases. © 2016 The Alzheimer's Association
  •  
25.
  • Berron, David, et al. (författare)
  • Hippocampal subregional thinning related to tau pathology in early stages of Alzheimer’s disease
  • 2022
  • Ingår i: Alzheimer's and Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 18:S1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Subregions in the medial temporal lobe (MTL) are affected early by Alzheimer’s disease (AD) pathology and subject to grey matter atrophy. Measuring the earliest AD-related atrophy in the hippocampus is challenging as region-of-interest (ROI) analyses of hippocampal subregional volumes collapse across voxels within anatomical subregions. PET imaging studies, however, report accumulation of tau pathology between anatomical subregions in the earliest disease stages (Berron et al., 2021) fitting reports from the neuropathological literature (Lace et al., 2019; Ravikumar et al., 2021). Thus, sensitive in vivo methods of point-wise structural measures are needed in order to detect the earliest hippocampal thinning in AD along the anterior-posterior as well as the medial-lateral hippocampal axis. Method: Here we analyzed data from 76 amyloid-beta negative (Ab-) cognitively normal (CN), 46 Ab+ CN individuals and 25 Ab+ patients with mild cognitive impairment (MCI) from the BioFINDER-2 study, who underwent 7 Tesla T2-weighted structural magnetic resonance imaging, tau positron emission tomography imaging (using 18F-RO-948) and cognitive assessments. First, we segmented hippocampal subfields and extrahippocampal subregions. Second, we calculated point-wise hippocampal thickness estimates (Diers et al.) of hippocampal subfields subiculum, cornu ammonis (CA)1, CA2 and CA3 on the level of the hippocampal body. Thirdly, we extracted local tau-PET SUVR from Area 35 (A35), entorhinal cortex and amygdala. Finally, we assessed relationships between hippocampal local thickness and tau accumulation as well as cognitive performance. Result: Our analyses revealed earliest hippocampal thinning associated with tau accumulation in an area spanning the boundary of subiculum and CA1 at the level of the anterior hippocampal body. Ab+ MCI patients showed more posterior thinning in comparison to Ab- CU participants. Median thickness in an ROI comprising vertices with A35 tau-related thinning (A35-TauThinning-ROI) was significantly lower in MCI Ab+ and tended to be lower in CU Ab+ compared to CU Ab-. Higher median thickness in the hippocampal A35-TauThinning-ROI, but not whole CA1 nor subiculum thickness, was associated with better 10-Word-Delayed-Recall and higher PACC scores. Conclusion: Our results suggest that tau-related thinning of hippocampal subregions can be observed already in early disease stages. Tau-related point-wise thickness measures were more sensitive compared to volumetric measures of anatomical subregions.
  •  
26.
  • Bilgel, M., et al. (författare)
  • Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid
  • 2023
  • Ingår i: Alzheimers & Dementia. - 1552-5260 .- 1552-5279. ; 19:10, s. 4335-45
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTIONUnderstanding longitudinal plasma biomarker trajectories relative to brain amyloid changes can help devise Alzheimer's progression assessment strategies. METHODSWe examined the temporal order of changes in plasma amyloid-beta ratio (A beta 42/A beta 40${{\rm A}\beta }_{42}/{{\rm A}\beta }_{40}$), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau ratios (p-tau181/A beta 42$\text{p-tau181}/\mathrm{A}{\beta}_{42}$, p-tau231/A beta 42$\text{p-tau231}/\mathrm{A}{\beta}_{42}$) relative to C-11-Pittsburgh compound B (PiB) positron emission tomography (PET) cortical amyloid burden (PiB-/+). Participants (n = 199) were cognitively normal at index visit with a median 6.1-year follow-up. RESULTSPiB groups exhibited different rates of longitudinal change in A beta 42/A beta 40(beta=5.41x10-4,SE=1.95x10-4,p=0.0073)${{\rm A}\beta }_{42}/{{\rm A}\beta }_{40}\ ( {\beta \ = \ 5.41 \times {{10}}<^>{ - 4},{\rm{\ SE\ }} = \ 1.95 \times {{10}}<^>{ - 4},\ p\ = \ 0.0073} )$. Change in brain amyloid correlated with change in GFAP (r = 0.5, 95% CI = [0.26, 0.68]). The greatest relative decline in A beta 42/A beta 40${{\rm A}\beta }_{42}/{{\rm A}\beta }_{40}$ (-1%/year) preceded brain amyloid positivity by 41 years (95% CI = [32, 53]). DISCUSSIONPlasma A beta 42/A beta 40${{\rm A}\beta }_{42}/{{\rm A}\beta }_{40}$ may begin declining decades prior to brain amyloid accumulation, whereas p-tau ratios, GFAP, and NfL increase closer in time.
  •  
27.
  • Binette, Alexa Pichet, et al. (författare)
  • Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
  • 2022
  • Ingår i: Alzheimer's and Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 18:S1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, it is important to understand how Aβ and soluble phosphorylated tau (p-tau) relate to the accumulation of tau aggregates assessed with positron emission tomography (PET) and subsequent cognitive decline across the Alzheimer's disease (AD) continuum. Method: We included 327 participants from the Swedish BioFINDER-2 cohort with cerebrospinal fluid (CSF) p-tau217, Aβ-PET, longitudinal tau-PET, and longitudinal cognition. The main groups of interest were Aβ-positive non-demented participants and AD dementia patients (Table 1 and Figure 1), and analyses were conducted separately in each group. First, we investigated how soluble p-tau217 and regional Aβ-PET were associated with tau-PET rate of change across the 200 brain parcels from the Schaefer atlas. We also tested the mediating effect of p-tau217 between Aβ-PET and tau-PET change. Second, we investigated how soluble p-tau217 and tau-PET change related to change in cognition, and mediation between these variables. Result: In early AD stages (non-demented participants), increased concentration of soluble p-tau217 was the main driver of accumulation of insoluble tau aggregates across the brain (measured as tau-PET rate of change), beyond the effect of regional Aβ-PET and baseline tau-PET (Figure 2A-C). Further, averaged across all regions, soluble p-tau217 mediated 54% of the association between Aβ and tau aggregation (Figure 2D). Higher soluble p-tau217 concentrations were also associated with cognitive decline, which was mediated by faster increase of tau aggregates (Figure 3). Repeating the same analyses in the AD dementia group, results were different. In late stage of AD, when Aβ fibrils and soluble p-tau levels have plateaued, soluble p-tau217 was not associated with accumulation of tau aggregates beyond baseline tau-PET (Figure 4A), and cognitive decline was driven by the accumulation rate of insoluble tau aggregates and not soluble p-tau217 (Figure 4B-C). Conclusion: Soluble p-tau is a main driver of tau aggregation and future cognitive decline in earlier stages of AD, whereas tau aggregation accumulation is more likely an important driver of disease in later stages. Overall, our data suggest that therapeutic approaches reducing soluble p-tau levels might be most favorable in early AD.
  •  
28.
  • Biskaduros, Adrienne, et al. (författare)
  • Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects
  • 2024
  • Ingår i: ALZHEIMERS & DEMENTIA. - 1552-5260 .- 1552-5279.
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: We examined whether hypertension (HTN) was associated with Alzheimer's disease-related biomarkers in cerebrospinal fluid (CSF) and how changes in blood pressure (BP) related to changes in CSF biomarkers over time. METHODS: A longitudinal observation of cognitively healthy normotensive subjects (n = 134, BP < 140/90, with no antihypertensive medication), controlled HTN (n = 36, BP < 140/90, taking antihypertensive medication), and 35 subjects with uncontrolled HTN (BP >= 140/90). The follow-up range was 0.5to15.6 years. RESULTS: Total tau (T-tau) and phospho-tau181 (P-tau 181) increased in all but controlled HTN subjects (groupxtime interaction: p < 0.05 for both), but no significant A beta 42 changes were seen. Significant BP reduction was observed in uncontrolled HTN, and it was related to increase in T-tau (p = 0.001) and P-tau 181 (p < 0.001). DISCUSSION: Longitudinal increases in T-tau and P-tau 181 were observed in most subjects; however, only uncontrolled HTN had both markers increase alongside BP reductions. We speculate cumulative vascular injury renders the brain susceptible to relative hypoperfusion with BP reduction.
  •  
29.
  •  
30.
  • Blennow, Kaj, 1958, et al. (författare)
  • Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.
  • 2015
  • Ingår i: Alzheimer's & dementia : the journal of the Alzheimer's Association. - : Wiley. - 1552-5279. ; 11:1, s. 58-69
  • Tidskriftsartikel (refereegranskat)abstract
    • Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show any effect on disease progression in clinical trials, conceivably because the AD subjects are already too advanced to derive clinical benefit from treatment and because diagnosis based on clinical criteria alone introduces a high misdiagnosis rate. Thus, well-validated biomarkers for early detection and accurate diagnosis are crucial. Low cerebrospinal fluid (CSF) concentrations of the amyloid-β (Aβ1-42) peptide, in combination with high total tau and phosphorylated tau, are sensitive and specific biomarkers highly predictive of progression to AD dementia in patients with mild cognitive impairment. However, interlaboratory variations in the results seen with currently available immunoassays are of concern. Recent worldwide standardization efforts and quality control programs include standard operating procedures for both preanalytical (e.g., lumbar puncture and sample handling) and analytical (e.g., preparation of calibration curve) procedures. Efforts are also ongoing to develop highly reproducible assays on fully automated instruments. These global standardization and harmonization measures will provide the basis for the generalized international application of CSF biomarkers for both clinical trials and routine clinical diagnosis of AD.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 479
Typ av publikation
tidskriftsartikel (435)
konferensbidrag (31)
forskningsöversikt (13)
Typ av innehåll
refereegranskat (458)
övrigt vetenskapligt/konstnärligt (21)
Författare/redaktör
Zetterberg, Henrik, ... (149)
Blennow, Kaj, 1958 (137)
Hansson, Oskar (53)
Skoog, Ingmar, 1954 (33)
Scheltens, Philip (30)
Ashton, Nicholas J. (30)
visa fler...
Ossenkoppele, Rik (30)
Soininen, Hilkka (23)
Schöll, Michael, 198 ... (23)
Stomrud, Erik (22)
Blennow, Kaj (21)
Teunissen, Charlotte ... (21)
Kivipelto, M (20)
Scheltens, P (20)
Visser, Pieter Jelle (20)
Hampel, Harald (20)
Tsolaki, Magda (19)
Kivipelto, Miia (19)
Zetterberg, Henrik (19)
Barkhof, Frederik (18)
Molinuevo, José Luis (18)
Karikari, Thomas (18)
Engelborghs, Sebasti ... (17)
Winblad, B (15)
Fratiglioni, Laura (15)
Frisoni, Giovanni B. (15)
Smith, Ruben (15)
Wimo, A (15)
Freund-Levi, Yvonne, ... (15)
Kern, Silke (14)
van der Flier, Wiesj ... (14)
Palmqvist, Sebastian (14)
Andreasson, Ulf, 196 ... (14)
Xu, Weili (14)
Soininen, H (13)
Vandenberghe, Rik (13)
Solomon, Alina (13)
Janelidze, Shorena (13)
Martínez-Lage, Pablo (13)
Nordberg, Agneta (13)
Jonsson, L. (12)
Wallin, Anders, 1950 (12)
Winblad, Bengt (12)
Mattsson-Carlgren, N ... (12)
Lleó, Alberto (12)
Shaw, Leslie M (12)
Barkhof, F (12)
Mattsson, Niklas (12)
Lovestone, Simon (12)
Grande, Giulia (12)
visa färre...
Lärosäte
Göteborgs universitet (241)
Karolinska Institutet (197)
Lunds universitet (90)
Stockholms universitet (50)
Uppsala universitet (21)
Örebro universitet (17)
visa fler...
Umeå universitet (13)
Jönköping University (12)
Luleå tekniska universitet (10)
Linköpings universitet (8)
Linnéuniversitetet (5)
Högskolan Kristianstad (4)
Södertörns högskola (3)
Karlstads universitet (3)
Gymnastik- och idrottshögskolan (2)
Högskolan Dalarna (2)
Röda Korsets Högskola (2)
Kungliga Tekniska Högskolan (1)
Mittuniversitetet (1)
Högskolan i Skövde (1)
RISE (1)
Marie Cederschiöld högskola (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (479)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (381)
Samhällsvetenskap (9)
Naturvetenskap (8)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy